SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Care-plan review) — Abraham Lincoln

PatientAbraham Lincoln
Date of birth1994-02-12
IdentifiersMRN HR-NI001-SYN; SSN (made up) 000-01-6683
Document date2026-09-30
AuthorElena Marquez, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Twelve-week depression care-plan review. [S]

History of Present Illness

Mr. Lincoln returns twelve weeks after starting sertraline 50 mg daily. He says he feels like himself again. He sleeps about seven hours, has kept up his court work and letters, and has added evening walks with a law colleague. His interest in his cases and his friends has returned, and his concentration is back to normal. He has had no side effects since the early nausea and still misses about one dose every two weeks. He has had no suicidal thoughts. The nurse telephone check planned for four weeks after his last visit did not take place. He asks how long he will need to keep taking the medicine. [S]

ElementDetail
Interval changeFeels like himself; interest and concentration back to normal
SleepAbout seven hours a night
Medication toleranceNo adverse effects since the early nausea
AdherenceMisses about one dose every two weeks
SafetyNo suicidal thoughts
PHQ-94, down from 14
Patient questionHow long to continue sertraline

Review of Systems

SystemResultFinding
ConstitutionalNegativeGood energy; weight up 1 kg since intake
GastrointestinalNegativeNo nausea, diarrhea, or bleeding
GenitourinaryNegativeNo sexual side effects
NeurologicalNegativeNo headache, tremor, or restlessness
PsychiatricNegativeMood good; sleeping well; no suicidal thoughts, elevated mood, or racing thoughts

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Sertraline 50 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-06-30activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-09-30Body height193cmS
2026-09-30Body weight83kgS
2026-09-30Body mass index (BMI) [Ratio]22.3kg/m2S
2026-09-30Systolic blood pressure114mm[Hg]S
2026-09-30Diastolic blood pressure72mm[Hg]S
2026-09-30Heart rate66/minS
2026-09-30Respiratory rate14/minS
2026-09-30Body temperature36.7CelS
2026-09-30Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-09-30Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S

Physical Exam

Vital signs recorded on 2026-09-30; see the Vital Signs section. [S]

SystemFinding
GeneralWell, relaxed, and good-humored
Mental statusAlert and oriented; mood "good"; affect full and reactive; thought process linear; no suicidal ideation or psychotic features; insight and judgment good
NeurologicalNo tremor

Problems

ProblemClinical statusVerificationCodeProvenance
Major depressive disorder, single episode, moderate; synthetic modern diagnosis linked to documented low mood and its retrospective interpretationactiveprovisional F32.1S — Synthetic active diagnosis for the teaching episode; the historical depression label remains R.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyPHQ-9Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuationCompleted today4, down from 14 at intake (71 percent): response and a remission-range score; the goal of below 5 is met
SurveyInterim PHQ-9 by nurse telephone checkAt least monthly during acute treatmentDeferredThe telephone PHQ-9 planned at the six-week visit for about four weeks later was not made, so seven weeks passed without a score, a second deviation from the monthly cadence. No harm resulted: he improved steadily and reports no suicidal thoughts in the interval. Corrective action: continuation-phase PHQ-9s every two to four weeks are booked, the first at his preventive visit in about four weeks
SurveySuicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9)Every visit during active treatmentCompleted todayNo suicidal thoughts, intent, plan, or behavior since the last visit; PHQ-9 item 9 scored 0. Safety plan reviewed and kept for the continuation phase
Medication safetyAdherence and adverse-effect reviewEvery visit during active treatmentCompleted todayMisses about one dose every two weeks; no adverse effects
Medication safetyTolerability check after a dose change1 to 2 weeks after each dose changeNot indicatedDose unchanged; no increase needed
Medication safetyContinuation of sertraline at the remission doseAt least six months after remissionUp to dateContinue 50 mg daily for at least six months, then review tapering together
ExaminationWeight, BMI, and blood pressureWith each tolerability checkCompleted todayWeight 83.0 kg, up 1.0 kg since intake; BMI 22.3; blood pressure 114/72 mmHg
ExaminationMental status examinationEvery visitCompleted todayFull, reactive affect; linear thinking; no suicidal ideation or psychotic features
SurveyMood Disorder Questionnaire (bipolar screen)Repeat if hypomanic features emergeNot indicatedBipolar disorder was not suspected at the psychiatry consultation, and no hypomanic features have appeared
LaboratoryDrug levels and metabolic laboratory monitoringLithium, valproate, carbamazepine, or second-generation antipsychotic therapyNot indicatedSertraline monotherapy needs no routine laboratory monitoring
ReferralPsychiatry reviewIf response stalls, after a failed dose increase, or for new riskUp to dateConsultation completed six weeks ago; none of the criteria for another review are met
ReferralPsychotherapy for relapse prevention (CBT, interpersonal therapy, or mindfulness-based cognitive therapy)In continuation for patients at high risk of relapseNot indicatedA single uncomplicated episode in stable remission is not high risk; it stays available if he wants it
Self-managementBehavioral activation and sleep routineEvery visitCompleted todayCourt work, letters, and evening walks continue; sleeping about seven hours

Goal progress:

Guideline basis: VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Adult preventive visit in about four weeks, with a PHQ-9. Depression review every two to four weeks in the continuation phase. Call the clinic or 988 at any time if his mood worsens. Next scheduled visit 2026-10-27: adult preventive visit. [S]